Shamburg News · 8-K filed Nov 16, 2026, 9:02 AM EST

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

ELOX · Eloxx Pharmaceuticals, Inc.

  • Earnings
  • Other event
  • Materiality: high

Eloxx Pharmaceuticals reported a net loss of $5.5 million, or $(0.49) per share, for the three months ended September 30, 2026, compared with a net loss of $0.4 million, or $(0.58) per share, a year earlier. As of September 30, 2026, the company had cash and cash equivalents of $56.3 million, which it believes will fund operations into 2028. The press release also described dosing of the first two patients in the Phase 2b EXACT study and FDA clearance of the IND for the EXPRESS study.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-462310.

Written from the filing by Shamburg Markets. Figures are as reported by the company.